Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes
SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that it it has …